Literature DB >> 7661475

Central venous catheterization via persistent left superior vena cava.

R K Josloff1, J S Kukora.   

Abstract

We describe the problems of clinical assessment of subclavian catheter placement whose course was noted to be along the left lateral border of the heart, suggesting malposition. After the catheter's position in a persistent left superior vena cava was confirmed by blood gas analysis, lateral chest X-ray film, and venography, the catheter was used to provide total parenteral nutrition without complications. The evaluation and workup of seeming malposition of central venous catheters and the embryologic development of a left-sided vena cava are discussed.

Mesh:

Year:  1995        PMID: 7661475

Source DB:  PubMed          Journal:  Am Surg        ISSN: 0003-1348            Impact factor:   0.688


  4 in total

1.  Persistent left superior vena cava: a reason for pseudodisplacement of a port catheter.

Authors:  L Schiffmann; M Kruschewski; F Wacker; H J Buhr
Journal:  Surg Radiol Anat       Date:  2003-04-03       Impact factor: 1.246

2.  Long-term central venous catheterization via persistent left superior vena cava: a case report.

Authors:  Lamberto Laurenzi; Sebastiano Natoli; Lorella Pelagalli; Maria Elena Marcelli; Daniele Abbattista; Livio Carpanese; Edoardo Arcuri
Journal:  Support Care Cancer       Date:  2003-01-16       Impact factor: 3.603

3.  [Implantation of a re-synchronization device in a patient with persistent left superior vena cava-a case report].

Authors:  D Reinhardt; R Surber; H Kuehnert; M Heinke; H R Figulla
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2006-03

Review 4.  Persistent left superior vena cava: review of the literature, clinical implications, and relevance of alterations in thoracic central venous anatomy as pertaining to the general principles of central venous access device placement and venography in cancer patients.

Authors:  Stephen P Povoski; Hooman Khabiri
Journal:  World J Surg Oncol       Date:  2011-12-28       Impact factor: 2.754

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.